SX-ELLA Danis-Stent for Refractory Acute Esophageal Variceal Bleeding

Pedro Currais\textsuperscript{a,b}  Gonçalo Nunes\textsuperscript{b,d}  Marta Patita\textsuperscript{b}  Élia Coimbra\textsuperscript{c}

Jorge Fonseca\textsuperscript{b,d}

\textsuperscript{a}Gastroenterology Department, Instituto Português de Oncologia de Lisboa, Lisbon, Portugal; \textsuperscript{b}Gastroenterology Department, Hospital Garcia de Orta, Almada, Portugal; \textsuperscript{c}Interventional Radiology Unit, Hospital Curry Cabral, Lisbon, Portugal; \textsuperscript{d}PaMNEC – Grupo de Patologia Médica, Nutrição e Exercício Clínico, CiiEM, Centro de Investigação Interdisciplinar Egas Moniz, Monte da Caparica, Portugal

Keywords
Danis-stent · Upper gastrointestinal bleeding · Esophageal varices

The authors describe a 78-year-old male with alcoholic liver cirrhosis (Child-Pugh score 9 points, Meld-Na 16 points, without active drinking habits for several years). The patient had clinically significant portal hypertension manifested as refractory ascites managed with repeated large volume paracentesis and five bleeding episodes from esophageal varices. During these bleeding events the patient was treated with multiple sessions of band ligation and sclerotherapy. Two days after being discharged from the hospital due to the last bleeding episode he was readmitted due to hematemesis with hypotension and anemia. After clinical stabilization and blood transfusion to reach safe hemoglobin levels (hemoglobin at admission: Hb 6.7 g/dL), upper GI endoscopy was performed, showing in the distal third of the esophagus (37 cm from the incisors), an esophageal varix with cherry-red spots and a white nipple sign suggestive of a rupture point (Fig. 1a). Band ligation was initially tried, which was not successful due to marked fibrosis that prevented the cord to enter in the cap for banding. A massive variceal bleeding developed causing loss of endoscopic view and an SX-ELLA Danis-stent (25 x 135 mm, fully covered) was placed under guidewire with immediate technical and clinical success (Fig. 1b). The proximal limit of SX-ELLA Danis-stent was located at 29 cm of the incisors. The patient progressed favorably with no evidence of further blood loss and ICU admission was not needed. Given the several episodes of variceal bleeding despite endoscopic therapy and refractory ascites, 7 days after the index procedure a Transhepatic Portosystemic Shunt (TIPS) VIATORR \textsuperscript{\textregistered} endoprosthesis with 7 mm was placed without complications reaching a...
hepatic venous pressure gradient of 11 mm Hg (from an initial 22 mm Hg) (Fig. 2). The Danis-stent was endoscopically removed using a foreign body forceps 11 days after its placement (Fig. 3). A marked reduction in the size of the esophageal varices and a whitish scarry area in the distal esophagus coincident with the previous rupture point were observed (Fig. 4). Clinical evolution was favorable with no further bleeding recurrence or hepatic encephalopathy and partial improvement of ascites. The patient was discharged and maintained follow-up on hepatology outpatient clinic.

Discussion

Portal hypertension is the hemodynamic abnormality associated with the most severe complications of liver cirrhosis, including ascites, hepatic encephalopathy, and bleeding from gastroesophageal varices. Variceal bleeding is a medical emergency associated with a mortality of 10–20% in 6 weeks [1].

The combination of vasoactive drugs and endoscopic therapy (preferably esophageal band ligation) are recommended as the main therapeutic modality for bleeding.
esophageal varices; however, it can be challenging in the presence of massive bleeding. In this scenario, as expressed in AASLD and EASL recommendations, fully covered self-expandable metallic stents and Sengstaken-Blakemore tubes (SBT) are viable options, recommended as bridge to a definitive therapy [1–3].

SBT are the most widely used, providing bleeding controls of 90%. However, it should only be used under intensive care facilities due to the high risk of severe and life-threatening complications. Dedicated fully covered self-expandable metallic stents (like SX-ELLA Danis-stent) have also been used in this setting, achieving an higher rate of bleeding control with a lower incidence of severe complications [4, 5]. In this clinical case the authors exemplify the use of an SX-ELLA Danis-stent as bridge for TIPS placement in a patient with massive variceal bleeding refractory to band ligation.

From the authors’ point of view, SX-ELLA Danis-stents should generally be favored over SBT placement due to its higher efficacy, less potential complications, and the fact that it can be used by endoscopists in a urgent setting even by those without experience in fluoroscopy. Also, as Danis-stent allows an immediate control of variceal bleeding, it will reduce the time needed for airway protection and ICU admission. Nevertheless, all emergency physicians should be able do use SBT and therefore it will retain its role in a facility without gastroenterology support and in all cases of uncontrolled bleeding from gastric varices where Danis-stent placement would not be effective.

**Statement of Ethics**

The authors declare that all ethical procedures were followed. The patient signed written consent, allowing use and divulgation of clinical information and images.

**Conflict of Interest Statement**

The authors have no conflicts of interest to declare. Moreover, they are aware that the manuscript’s copyright belongs to GE – Portuguese Journal of Gastroenterology.

**Funding Sources**

No funding resources were used in the elaboration of the article.

**Author Contributions**

Gonçalo Nunes – patient evaluation, clinical data collection and performed the endoscopic procedure; Marta Patita – patient evaluation and clinical data collection; Elia Coimbra – performed the TIPS placement and gave these figures for publication; Pedro Currais – manuscript draft; Gonçalo Nunes and Jorge Fonseca – critical review of the manuscript.

**Data Availability Statement**

All the data and exams related to this clinical case are available on Hospital Garcia de Orta informatic system.
References

1 de Franchis R; Baveno VI Faculty. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015 Sep;63(3):743–52.

2 Angeli P, Bernardi M, Villanueva C, Francoz C, Mookerjee RP, Trebicka J, et al.; European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver.

3 Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology. 2017 Jan;65(1):310–35.

4 Escorsell À, Pavel O, Cárdenas A, Morillas R, Llop E, Villanueva C, et al.; Variceal Bleeding Study Group. Esophageal balloon tamponade versus esophageal stent in controlling acute refractory variceal bleeding: A multicenter randomized, controlled trial. Hepatology. 2016 Jun;63(6):1957–67.

5 Pfisterer N, Riedl F, Pachoszky T, Gschwantler M, König K, Schuster B, et al. Outcomes after placement of a SX-ELLA oesophageal stent for refractory variceal bleeding – A national multicentre study. Liver Int. 2019 Feb;39(2):290–8.